To include your compound in the COVID-19 Resource Center, submit it here.

eGenesis pushes to bring pig organ transplants to humans with $100M series B

eGenesis is aiming to be the first to transplant genetically engineered pig organs into humans with its $100 million series B round, which will allow the Cambridge, Mass.-based company to advance multiple programs in parallel.

Fresenius Medical Care Ventures led the untranched round. New investors Leaps by Bayer

Read the full 487 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers